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Abstract
Background: Unsaturated fatty acids (FA) are required for cancer cell growth. In normoxia cells can generate
unsaturated FA from saturated stearic and palmitic acid by desaturation. However, since the desaturation step is
oxygen-dependent hypoxic cancer cells display an increased dependence on the uptake of unsaturated FA. Up to
now the mechanism of increased FA uptake in hypoxia is largely unknown. Here we aimed to study the role of
human serum and glucocorticoid-inducible kinase (SGK1) in the regulation of FA uptake in cancer cells exposed to
acute or chronic cycling hypoxia and explore its use as target for the radiosensitization of hypoxic cancer cells.
Methods: The effect of SGK1-inhibition (GSK650394) on NCI-H460 lung adenocarcinoma cells exposed to normoxia,
acute or chronic cycling hypoxia was analyzed under standard and serum-deprived conditions by short-term proliferation,
apoptosis and cell death assays. The impact of SGK1-inhibition on radiation sensitivity was determined by standard colony
formation assays. The effect of GSK650394 on FA uptake was quantified by measuring intracellular accumulation
of fluorescent FA (C1-BODIPY®-C12).
Results: Exposure to acute or chronic cycling hypoxia was associated with up-regulated expression of SGK1 in
NCI-H460 cells, increased uptake of FA from the culture medium, and increased sensitivity to serum deprivation.
Survival of serum-deprived hypoxic NCI-H460 cells was rescued by the addition of the unsaturated FA, oleic acid,
whereas the saturated FA, palmitic acid was highly toxic to the hypoxic cancer cells. Interestingly, SGK1 inhibition
abrogated the rescue effect of oleic acid in serum-deprived hypoxic cancer cells and this effect was associated
with a reduction in FA uptake particularly in anoxia-tolerant cancer cells exposed to severe hypoxia. Finally, SKG1
inhibition decreased long-term survival and potently sensitized the parental and anoxia-tolerant NCI-H460 cells to
the cytotoxic effects of ionizing radiation in normoxia as well as the anoxia-tolerant cancer cells in severe hypoxia.
Conclusions: Our data suggest that SGK1 plays a role in the regulation of FA uptake that becomes essential under
conditions of acute or chronic cycling hypoxia. We assume that SGK1 may represent a promising therapeutic target for
the eradication of hypoxic cancer cells.
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Background
Tumor hypoxia is a common feature of solid human tu-
mors and constitutes a major obstacle to successful radio-
therapy [1, 2]. Tumor hypoxia, which is characterized by
reduced tissue oxygenation, arises either as acute hypoxia
resulting for example from a disturbed microcirculation or
reversible occlusion of tumor blood vessels, or as chronic
hypoxia for example as a result of the increased oxygen dif-
fusion distance to the capillary in rapidly growing tumors
[3–9]. Acute and chronic hypoxia as well as moderate and
severe hypoxia can coexist in the same tumor; thereby tu-
mors are exposed to a continuum of varying high and low
oxygen partial pressures [3, 6, 8, 10, 11]. Tumor hyp-
oxia can also be highly dynamic with cycles of hypoxia
and intermittent re-oxygenation termed cycling hypoxia
[4, 10, 12, 13]. Tumor hypoxia promotes phenotypic
heterogeneity, malignant progression and clonal evolution
of chemotherapy and radiotherapy resistance, among
others by hypoxia-induced genomic instability and adap-
tive changes in cell metabolism [8, 14–17].
One major metabolic pathway affected by hypoxia is
the lipid metabolism [18, 19]. Cell growth, proliferation
and survival involve the formation of new membranes,
which require the production of new lipids with an ap-
propriate molecular composition. The process by which
acetyl coenzyme A is converted to fatty acids (FA) is
named lipogenesis [18, 20]. The basic step in this
pathway is the oxidation of saturated FA into mono-
unsaturated FA that serve as a major FA species in
mammalian membranes, cell signaling and as a pool of
metabolic energy, respectively [18, 21]. The oxidation
step is catalyzed by stearoyl-CoA desaturase (SCD1), a
FA desaturase expressed in most adult tissues. The en-
zyme is responsible for maintaining the balance of satu-
rated FA and unsaturated FA by converting absorbed
exogenous and endogenously synthesized saturated FA
into (mono)-unsaturated FA [18, 22]. It was generally
assumed that tumor cells synthesize most of the non-
essential FA autonomously. However, a recent study re-
vealed that the provision of unsaturated FA for cancer
cell growth is highly dependent on oxygen supply to
ensure the availability of sufficient unsaturated FA [23].
In normoxia, high FA synthesis emerges from glucose
metabolites [18, 24]. During this process, saturated FA
are formed, desaturated by SCD1, and subsequently
elongated. However, hypoxia leads to inhibition of the
oxygen-consuming enzyme SCD1 [18, 22]. The result-
ing impairment of the desaturation process leads to in-
creased dependence of hypoxic cancer cells on the
uptake of unsaturated FA from the environment for
maintaining cellular processes such as membrane for-
mation and signaling [19, 23]. A similar dependency on
the uptake of unsaturated FA is achieved in normoxic
cells by inhibition of SCD1 [25, 26].
Up to now, the molecular mechanisms that mediate
and control the uptake of FA from the environment are
widely unknown. But a recent study performed in yeast
suggested that the expression of YPK1, the yeast ortho-
log of human serum and glucocorticoid-inducible kinase
SGK1, is linked to FA uptake and cell growth in hypoxia
[27]. SGK1 is a serine/threonine-kinase with a highly
conserved kinase structure that is ubiquitously expressed
in human tissues and activated by growth factors and hor-
mones via the PI3-Kinase pathway [28–34]. Since our pre-
liminary data suggested a prominent up-regulation of
SGK1 in hypoxia we speculated that in addition to its re-
ported role in the activation of various ion channels and
nutrient transporters SGK1 might regulate the FA uptake
in cancer cells.
The present study was designed to investigate a de-
pendency of NCI-H460 lung adenocarcinoma cells ex-
posed to acute severe hypoxia (0.2 % O2) on the uptake
of (unsaturated) FA present in serum and to evaluate the
role of SGK1 in regulating this process. In addition, we
were interested whether chronic exposure of NCI-H460
lung cancer cells to 25 cycles of anoxia (48 h 0.1 % O2)/
re-oxygenation stress (120 h 20 % O2) changes the meta-
bolic dependencies of these “anoxia-tolerant cells” [16].
Finally, we aimed to explore the potential of SGK1-
inhibition to increase the cytotoxic activity of ionizing




GSK650394 was purchased from Tocris (Bristol, UK).
Fluorescent FA (C1-BODIPY® 500/510 C12) were purchased
from Thermo Scientific (MA, US). Propidium iodide (PI)
was from Gibco/Life Technologies (Carlsbad, CA). Stock
solutions of GSK650394 were made with DMSO. All other
chemicals were purchased from Sigma-Aldrich (St. Louis,
MO) if not otherwise stated.
The following antibodies were used for western blot
analysis: anti-goat SGK1 (C-20) and anti-rabbit Calnexin
(H-70) from Santa Cruz Biotechnology (Heidelberg,
Germany).
Cell lines and treatment
The lung adenocarcinoma cell line NCI-H460 was ob-
tained from ATCC (Bethesda, MD). NCI-H460
lung adenocarcinoma cells with tolerance to cycling se-
vere hypoxia/re-oxygenation stress (“anoxia-tolerant
cells”) were generated by exposure to 25 cycles of se-
vere hypoxia (48 h, 0.1 % O2) and re-oxygenation
(120 h air plus 5 % CO2 referred as 20 % O2) as de-
scribed recently [16]. Cells were routinely grown in
RPMI 1640 medium supplemented with 10 % (v/v) fetal
calf serum (Gibco/Life Technologies, Carlsbad, CA) and
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maintained in a humidified incubator at 37 °C and 5 %
CO2 (referred to as “normoxia“or “normoxic condi-
tions“, Nx). Under hypoxic conditions cells were grown
in a humidified hypoxia workstation (In vivo 400, Ruskinn
Technology Ltd., Bridgend, Great Britain) at 37 °C, 0.2 %
O2, and 5 % CO2 (referred to as “hypoxia” or “hypoxic
conditions“, Hx).
Serum withdrawal experiments started 4 h after seeding
by medium exchange to low serum media (0.5 % FCS).
Cells were treated with irradiation (0-10 Gy) without or
with SGK1 inhibitor (0–100 μM GSK650394) 24 h (h)
after seeding for up to 72 h. Lipid supplementation
(50 μM oleic acid (OA) or 50 μM palmitic acid (PA)) was
performed 24 h after seeding for up to 72 h. For combined
treatment, drugs were added 2 h before irradiation. For
treatment under hypoxic conditions, cells were transferred
to the hypoxic chamber 2 h before drug treatment.
0.1 % DMSO was used as a solvent control in all treat-
ment experiments. Irradiation was performed at room
temperature with an X-ray machine (Precision X-Ray
Inc., North Branford, CT) operated at 320 kV, 12.5 mA
with a 1.65 mm Al filter, at a distance of 50 cm and a
dose rate of 3.71 Gy/min. Cells were returned to the incu-
bator immediately after exposure to ionizing radiation.
qRT-PCR analysis
cDNA was synthesized from 1 μg of total RNA using
QuantiTect® Reverse Transcription Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol.
Specific primers were synthesized based on available se-
quences for each listened gene. Primer sets for quanti-
tative real-time PCR (qRT–PCR) were designed with
the program Primer 3 [35]. To exclude cross-reaction
of primers with the genes the sequence of interest was
compared with a database (Blast 2.2, U.S. National
Centre for Biotechnology Information, Bethesda, MD)
and all primers used in our study were intron-spanning.
PCR products were 300–400 bp in size. We used pub-
lished β2-microglobulin (B2M) primer sequences as
housekeeping gene [36]. qRT–PCR and cycling condi-
tions were performed using specific oligonucleotide primers
(B2M forward: TGCTGTCTCCATGTTTGATGTATCT;
reverse, TCTCTGCTCCCCACCTCTAAGT; SGK1: for-
ward, TGTTCATGGGAAACTCAATCTG; reverse,
TTGCATGCATAGGAGTTATTGG) using qPCR kit for
SYBR® Green I, 6-Carboxyl-X-Rhodamine (ROX) (Eurogen-
tec, Cologne, Germany) according to the manufacturers
protocol. Reactions were carried out on an ABI Prism
7900HT using MicroAmp Optical 96 well Reaction
plate (Applied Biosystems by Life Technologies, Bleijs-
wijk, Netherlands) and BIO-RAD PCR Sealers Microseal
“B” Film Adhesive seal (optically clear; BIORAD, Munich,
Germany). Melting curves were obtained after each PCR
run and showed single PCR products. cDNAs were run in
triplicate, without reverse transcriptase and no-
template controls were run in duplicates. Expression
levels for the genes of interest and for the housekeeping
gene B2M were measured in three independent PCR
runs. Expression ratios were calculated using the geometric
mean expression of the housekeeping gene B2M to
normalize the expression data for the genes of interest ac-
cording to the 2-ΔΔCt – method as described by others [37].
Western blot analyis
Cells were lysed in 200 μl of lysis buffer containing
50 mM Hepes (pH 7.5), 150 mM NaCl, 1 % Triton X-
100, 1 mM EDTA, 10 mM sodium pyrophosphate,
10 mM NaF, 2 mM Na3VO4, 100 mM PMSF, 5 μg/ml
aprotinin, 5 μg/ml leupeptin, and 3 μg/ml pepstatin.
Proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) under
reducing conditions and transferred onto polyvinyli-
dene fluoride (PVDF) membranes (Roth, Karlsruhe,
Germany). Blots were blocked in TBS buffer containing
0.05 % Tween 20 and 5 % non-fat dried milk for 1 h at
room temperature. The membrane was incubated over-
night at 4 °C with the respective primary antibodies.
The secondary antibody was incubated for 1 h at room
temperature. Detection of antibody binding was per-
formed by enhanced chemiluminescence (ECL Western
Blotting Analysis System; GE Healthcare/Amersham
Biosciences, Freiburg, Germany). Equal protein loading
was verified by calnexin-staining. Densitometric analysis
was performed using ImageJ 2.00, National Institutes of
Health, Bethesda, MD).
Determination of fatty acid uptake
The uptake of FA was quantified by using fluorescent
FA analog C1-BODIPY® 500/510 C12. In brief, fluores-
cent FA (5 μM) were added 24 h after treatment to
serum-free media. We quenched the fluorescence of FA
in media by adding trypan blue (0.33 mM) to the
media. The uptake of fluorescent FA was measured for
1 h, in 1 min intervals, at 37 °C spectrophotometrically
at 485/528 nm.
Flow cytometry analysis
For quantification of apoptotic DNA fragmentation
(subG1 population), cells were incubated for 30 min at
room temperature with a staining solution containing
50 μg/ml PI in a hypotonic citrate buffer 0.1 % (w/v)
sodium citrate and 0.05 % (v/v) Triton X-100 and sub-
sequently analyzed by flow cytometry (Flow Cytometer
BD Accuri™ C6, BD Bioscience, Heidelberg, Germany;
FL-2) [38].
Cell death was quantified by flow cytometry (Flow
Cytometer BD Accuri™ C6, Becton Dickinson) of PI–
stained cells. Cells were incubated for 30 min in the
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dark with PI (0.01 mg/ml) in PBS and measured within
1 h (Flow Cytometer BD Accuri™ C6, BD Bioscience,
Heidelberg, Germany; FL-2).
Cell viability assay
Cells were washed with PBS (1x), fixed with Glutaralde-
hyde (0.1 % in PBS), and stained with crystal violet
(0.1 % in PBS). The dye was released by TritonX-100
(0.2 % in PBS) and measured spectrophotometrically at
540 nm as described elsewhere [39].
Colony formation assay
Clonogenic cell survival in response to the respective
treatments was determined comparing cells cultured
under normoxic and severely hypoxic conditions. For
treatment in normoxia (Nx), exponentially growing cells
were seeded in tissue culture flasks, incubated under
standard culturing conditions (20 % O2, 5 % CO2, 37 °C)
and irradiated 24 h later (0 to 5 Gy) without or with
drug treatment. Drug treatment was performed 2 h prior
to irradiation treatment. For treatment in hypoxia (Hx),
tissue culture flasks of exponentially growing cells were
transferred into the hypoxic chamber 2 h prior to drug
treatment and 4 h prior to irradiation, respectively. After
completion of treatment, cells were incubated for 24 h
under standard or hypoxic conditions. Cells were then
collected (0.05 % Trypsin, 0.01 EDTA), washed, plated to
6 well plates at densities of 200 to 3200 cells per well,
and subsequently incubated for 10 days under standard
normoxic conditions.
For quantification of colony formation, cells were fixed
in 3.7 % formaldehyde and 70 % ethanol, stained with
0.05 % Coomassie blue and colonies of at least 50 cells
were counted by GelCount (Oxford Optronix, Oxfordshire,
Great Britain). The plating efficiency and surviving fraction
(SF) were calculated as described elsewhere [40].
Statistics
Data represent mean values of at least 3 independent ex-
periments ± standard deviation (SD). Data analysis was
performed either by unpaired students t-test or by two-
way ANOVA test (Prism5TM software, Graph Pad Inc., La
Jolla, US states) using parametric methods and employing
Bonferroni multiple comparison post-test where appropri-
ate. P-values ≤ 0.05 were considered significant.
Results
SGK1 expression increases in severe hypoxia and
promotes FA uptake
To examine deregulated expression of SGK1 in NCI-
H460 cells exposed to acute or chronic cycling hypoxia
we determined the SGK1 mRNA and protein expression
levels of parental (“oxic”) NCI-H460 cells and anoxia-
tolerant NCI-H460 control cells exposed to normoxia
(20 % O2) or acute severe hypoxia (0.2 % O2) by quantita-
tive RT-PCR (qRT-PCR) or western blot (WB). As shown
in Fig. 1a, anoxia-tolerant cells were characterized by sig-
nificant higher SGK1 mRNA expression levels under nor-
moxic conditions. However, exposure to acute severe
hypoxia led to a significant increase in SGK1 expression
in both cell lines pointing to a potential role of SGK1 in
the response of the lung cancer cells to acute severe hyp-
oxia (Fig. 1a). Our data were supported by Western blot
analysis showing increased expression of SGK1 in the
anoxia-tolerant cells compared to oxic control cells in
normoxia as well as an increased expression of SGK1 in
both cell lines on exposure to hypoxia (Fig. 1b).
Next we aimed to verify our hypothesis on a role of
SGK1 in FA uptake. For this, we measured the effect of
treatment with a specific SGK1 inhibitor (GSK650394)
on the uptake of fluorescently labeled FA in oxic and
anoxia-tolerant NCI-H460 cells exposed to normoxic
and severely hypoxic conditions. We chose a concentra-
tion of 40 μM on the basis of LC50 values of 40 to
100 μM obtained in cell-based in vitro assays by others
[41]. SGK1 inhibition did not significantly alter the up-
take of FA under normoxic conditions in both cell lines,
though a slight increase in FA uptake on treatment with
GSK650394 was observed (Fig. 1c). However, exposure
to severe hypoxia triggered a significant increase in the
uptake of FA in both cell lines to a similar extent. Im-
portantly, the hypoxia-induced increase in FA uptake
was significantly reduced in both cell variants upon
treatment with the SGK1 inhibitor (Fig. 1c). These ob-
servations implicate that SGK1 plays a role in the regu-
lation of FA uptake in severe hypoxia.
Acute and chronic cycling hypoxia leads to dependence
on unsaturated FA whereas saturated FA exert
toxic effects
Next we compared the role of FA for short-term cell
survival of parental (oxic) and anoxia-tolerant NCI-
H460 cancer cells in normoxic and severely hypoxic
conditions. For this, survival of oxic and anoxia-tolerant
cells was compared in standard medium versus serum-
deprived culturing conditions. While serum deprivation in
normoxia had no effect on survival of oxic control cells
compared to culturing in standard medium (Fig. 2b-d)
anoxia-tolerant cells turned out to be slightly sensitive to
serum deprivation in normoxia (Fig. 2d, lower panel). In
contrast, serum deprivation combined with severe hypoxia
led to a pronounced increase in the levels of apoptosis
and cell death in both cell variants (Fig. 2b, c, e). When
comparing the fold-changes in apoptosis or cell death
upon serum withdrawal, the anoxia-tolerant cells were
more sensitive to serum deprivation in severe hypoxia
compared to the oxic control cells (Fig. 2c, e). Further, we
tested whether the dependence of oxic and anoxia-
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tolerant cells on serum may be mediated by SGK1 and
therefore analyzed the mRNA expression levels of SGK1
under serum-deprived conditions. These data showed a
significant decrease in hypoxia-induced SGK1-expression
as a response to serum deprivation in hypoxia (oxic cells:
FC = 3.9 ± 0.8 versus 11.0 ± 4.8 in full medium; anoxia-
tolerant cells, Hx: FC = 5.2 ± 0.8 versus 12.3 ± 5.2 in full
medium), whereas serum-deprived condition had no sig-
nificant effect on mRNA SGK1 expression levels in nor-
moxia. To analyze whether the toxic effect of serum
deprivation was due to a deficiency in provision of unsat-
urated FA, we tested whether we could increase cell sur-
vival by supplementation of the medium with unsaturated
FA (oleic acid), saturated FA (palmitic acid), or the com-
bination of both (Fig. 2a). While supplementation of
serum-deprived NCI-H460 cells with oleic acid or palmitic
acid alone or in combination did not alter their survival in
normoxia (Fig. 2b, c, d), the addition of oleic acid reduced
apoptosis induction and rescued NCI-H460 cancer cells
from the toxic effects of serum deprivation in severe hyp-
oxia (Fig. 2c, e). In contrast supplementation of serum-
deprived hypoxic NCI-H460 cancer cells with palmitic
acid, a saturated FA, was even more toxic to hypoxic can-
cer cells than serum deprivation alone (Fig. 2b, c, e). How-
ever, the addition of palmitic acid was not able to
counteract the rescue effect of oleic acid under serum-
deprived conditions (Fig. 2b, c, e). Altogether these
findings corroborate the importance of supplementa-
tion with unsaturated FA for survival of cancer cells in
(severe) hypoxia and highlight a particular dependence
of anoxia-tolerant cells on oleic acid supplementation.
SGK1 inhibition abrogates the rescue effect of oleic
acid-supplementation
To investigate a potential role of SGK1 for cell survival
under the diverse conditions, the SGK1 inhibitor
GSK650394 was used according to the treatment schedule
depicted in Fig. 2a. Inhibition of SGK1 in serum-deprived
cells resulted in a significant decrease in proliferation and
increase of cell death levels under normoxic (Fig. 3a, b, c)
and severely hypoxic conditions (Fig. 3a, b, d). To verify
the suggested role of SGK1 in FA uptake we tested
whether SGK1-inhibition affects the beneficial effect of
oleic acid supplementation in serum-deprived cancer cells.
Interestingly, inhibition of SGK1 abrogated the rescue ef-
fect of oleic acid supplementation on cell death induced
by serum deprivation in severe hypoxia (Fig. 3a, b, d).
These results clearly demonstrate a general pro-survival
effect of SGK1 in oxic and anoxia-tolerant NCI-H460 can-
cer cells under normoxic and severely hypoxic conditions
and support a contribution of SGK1 in the regulation of
FA uptake in severe hypoxia.
SGK1 inhibition decreases long-term survival and
sensitizes to ionizing radiation
To investigate whether we can exploit the dependency
on SGK1 and FA uptake in a more clinical relevant set-
ting for increasing sensitivity to radiotherapy, we next
Fig. 1 SGK1 expression increases under hypoxia and regulates fatty acid uptake. NCI-H460 cells were exposed to acute (24 h 0.2 % O2) or chronic
cycling hypoxia (25 cycles of severe hypoxia (48 h, 0.1 % O2) and re-oxygenation (20 % O2)). a The expression of SGK1 in NCI-H460 cells was
determined using qRT-PCR analysis. Anoxia-tolerant cells displayed a significant increase in the expression of SGK1 compared to oxic control
cells under normoxia. Both cell lines showed a pronounced up-regulation of SGK1 mRNA in severe hypoxia. b Western blot analysis of SGK1
protein expression. Upper panel shows representative Western blots of SGK1 and calnexin expression levels. Lower panel shows densitometric
evaluation of SGK1 levels normalized to calnexin expression under the respective conditions. SGK1 protein levels were significantly increased in
anoxia-tolerant cells compared to oxic control cells in normoxia as well as in response to severe hypoxia in both cell lines. c The impact of SGK1 inhibition
by GSK650394 (40 μM for 24 h) on the uptake of FA was quantified under normoxic and severely hypoxic conditions in parental and anoxia-tolerant
NCI-H460 cells by using the fluorescent FA analogue C1-BODIPY® 500/510 C12. SGK1-inhibition by GSK650394 did not significantly alter
FA-uptake in normoxia, but significantly decreased the uptake of FA in severe hypoxia in both cell lines. Data show representative Western
blots or mean values ± SD are shown, n = 3. (* p ≤ 0.05, ** p < 0.01; unpaired students t-test)
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Fig. 2 Hypoxia leads to dependence on unsaturated FA whereas saturated FA exert toxic effects. To analyze the influence of serum deprivation
and lipid supplementation on the survival of oxic and anoxia-tolerant NCI-H460 cells, cells were cultured for 72 h in standard medium (10 %FCS)
or serum-deprived medium (0.5%FCS) without or with additional supplementation of saturated (50 μM palmitic acid, PA) or unsaturated FA
(50 μM oleic acid, OA). a Schematic representation of the experimental timeline. b Representative light microscopic pictures of NCI-H460 cells
72 h after treatment under the indicated conditions in normoxia (20 % O2) or severe hypoxia (0.2 % O2). Scale bar = 10 μM. c Representation of
the increase in apoptosis as heat map (fold changes; FC). Apoptosis induction was quantified 72 h after treatment by measuring DNA fragmentation upon
staining of the cells with PI in a hypotonic citrate buffer (subG1 fraction). d, e Cell death was quantified 72 h after treatment by flow cytometry upon
staining the cells with PI under normoxic (d) or severely hypoxic (e) conditions. The increase in cell death levels by a particular treatment is visualized in a
heat map representing fold changes (d lower panel, e lower panel). Almost no effect on apoptosis induction (c) or cell death levels (d) was observed in
both cell lines under indicated treatment conditions in normoxia. Serum deprivation and supplementation of palmitic acid induced apoptosis and
increased cell death levels in both cell lines in severe hypoxia, particularly in anoxia-tolerant NCI-H460 cells (c, e). Supplementation of oleic acid abolished
the increase in apoptosis and cell death induced by serum-deprivation without or with PA-supplementation in both cell lines under severe hypoxia (c, e).
Mean values ± SD are shown, n= 3. (* p ≤ 0.05, *** p ≤ 0.001; two- way ANOVA with Bonferroni post-test)
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tested the effect of GSK650395 alone and in combin-
ation with ionizing radiation on long-term survival of
oxic and anoxia-tolerant NCI-H460 cells (Fig. 4a, b).
As expected, the number of clonogenic cells declined
in both cell lines with increasing radiation dose and sig-
nificantly higher fractions of anoxia-tolerant cells survived
compared to oxic controls particularly upon irradiation
with 5 Gy under normoxic (Fig. 4a) and severely hypoxic
conditions (Fig. 4b). Interestingly, treating the cells with
GSK650394 largely decreased the number of clonogenic
oxic and anoxia-tolerant cells under normoxic conditions
(Fig. 4a). Combining ionizing radiation and GSK650394
resulted in almost complete eradication of clonogenic
tumor cells in both cell lines (Fig. 4a). Treating the cells
with GSK650394 alone decreased the number of clono-
genic cells in both cell lines in severe hypoxia, but to a
lesser extent compared to normoxia (Fig. 4b). Interest-
ingly, under severely hypoxic conditions combined treat-
ment with GSK650394 increased only the cytotoxic effect
of ionizing radiation in anoxia-tolerant cancer cells but
was almost without additional effect in the oxic NCI-
H460 control cells (Fig. 4b). Our data reveal that SGK1-
inhibiton is a promising approach for the eradication of
normoxic, hypoxic and anoxia-tolerant cancer cells and is
even able to sensitize anoxia-tolerant NCI-H460 cancer
cells with increased resistance to radiation-induced cell
death to the cytotoxic effects of ionizing radiation in nor-
moxia and severe hypoxia.
Discussion
There is a high need for new therapeutic approaches
suited to overcome hypoxia-mediated therapy resistance.
Fig. 3 SGK1 inhibition abrogates the rescue effect of oleic acid. Oxic and anoxia-tolerant NCI-H460 cells were treated with the SGK1 inhibitor
GSK650394 (40 μM) under serum-deprived conditions with or without supplementation of oleic acid (5 mM) for 24 h under normoxic (20 % O2)
or severely hypoxic conditions (0.2 % O2). a Representative light microscopic pictures of oxic and anoxia-tolerant NCI-H460 cells 72 h after the
indicated treatment under normoxic or severely hypoxic conditions. Scale bar = 10 μM. b Number of viable cells determined by crystal violet assay
72 h after the indicated treatments in normoxia (upper panel) or severe hypoxia (lower panel). c, d Cell death was quantified 72 h after treatment
by flow cytometry as described in Fig. 2. The increase in cell death levels by a particular treatment was visualized in a heat map representing fold
changes in normoxia (c, lower panel) and severe hypoxia (d, lower panel). SGK1 inhibition by GSK650394 decreased cell viability and increased
the amount of dead cells in both cell lines under normoxic (b upper panel, c) and severely hypoxic conditions (b lower panel, d). Cell death
induction was more prominent in anoxia-tolerant NCI-H460 cells (c lower panel, d lower panel). SGK1 inhibition abrogates the rescue effect of
supplementation with oleic acid (50 μM) on serum deprivation induced cell death under severely hypoxic conditions (b-d). Mean values ± SD are
shown, n = 3. (* p ≤ 0.05, *** p ≤ 0.001; two-way ANOVA with Bonferroni post-test)
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Here we show for the first time that SGK1 is important
to FA uptake of NCI-H460 lung adenocarcinoma cells
that becomes essential for cell survival under conditions
of severe hypoxia. Interestingly, dependency on SGK1
and FA supply for cell survival in hypoxia was main-
tained in anoxia-tolerant NCI-H460 cells with increased
resistance to radiation-induced cell death due to adap-
tion to chronic cycling hypoxia-reoxygenation stress.
Fig. 4 SGK1 inhibition decreases long-term survival and sensitizes to ionizing radiation. Colony formation of oxic and anoxia-tolerant NCI-H460
cells upon treatment with SGK1 inhibitor GSK650394 (5 μM), ionizing radiation (2 or 5 Gy), or the combination (pretreatment with GSK650394 for 2 h)
under normoxic (20 % O2), a) and severely hypoxic conditions (0.2 % O2), b). Treatment in severe hypoxia was performed 2 h after pre-incubation in
hypoxia. Upper panels show representative pictures of colonies formed after 10 days in normoxia (a) or severe hypoxia (b) as indicated. Values were
normalized to the plating efficiency of the respective untreated cells. Lower panels represent quantification of the surviving fraction normalized to the
plating efficiency of non-irradiated cells. Anoxia-tolerant NCI-H460 cells are characterized by increased radiation resistance as demonstrated by increased
surviving fractions of anoxia-tolerant NCI-H460 cells compared to oxic controls upon exposure to ionizing radiation in normoxia (a) or hypoxia (b). SGK1
inhibition alone significantly reduced the number of clonogenic tumor cells in both cell lines. The effect was more prominent under normoxic conditions
(a). (Pre-)treatment with GSK650394 was highly effective in reducing the surviving fraction of anoxia-tolerant NCI-H460 cells and potently sensitized both
cell lines to the cytotoxic action of ionizing radiation under normoxic conditions (a). Combined treatment with ionizing radiation and GSK650394 under
severely hypoxic conditions only decreased the numbers of clonogenic anoxia-tolerant cells but was almost without effect on the oxic control cells.
Mean values ± SD are shown, n = 3. (* p ≤ 0.05, ** p < 0.01, *** p ≤ 0.001; two- way ANOVA with Bonferroni post-test). IR, ionizing radiation
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Even more important, pharmacologic inhibition of SGK1
resulted in efficient eradication of clonogenic NCI-H460
cells when given alone or in combination with ionizing
radiation, including anoxia-tolerant cells treated in
severe hypoxia.
In more detail, we found that the toxic effect of
serum deprivation on parental and anoxia-tolerant NCI-
H460 cells could be rescued by supplementation with
the mono-unsaturated FA oleic acid. These findings cor-
roborate earlier observations on the dependency of A549
cancer cells on the uptake of unsaturated FA under hyp-
oxic conditions [23]. The authors demonstrated that
RAS-stimulated scavenging of serum FA instead of de
novo lipogenesis from glucose rendered those cancer
cells resistant to hypoxia as well to inhibitors of the
oxygen-dependent enzyme SDC1 that operates in the
glucose-dependent de novo lipogenesis pathway [21, 23,
42]. However, here we show in addition that dependency
of RAS-driven NCI-H460 cells on exogenously added
unsaturated FA and FA uptake for survival in hypoxia is
maintained in an anoxia-tolerant cell variant that has
been generated by chronic exposure to hypoxia-re-
oxygenation stress [16]. Furthermore, we uncovered
SGK1 as a regulator of FA uptake from a hypoxic tumor
environment, thereby offering new options for the treat-
ment of these highly radiation resistant cells (Fig. 5).
First hints to a potential role of kinases of the SGK1
family in FA uptake were provided by a study in yeast
(Saccharomyces cerevisiae) [27]. The authors showed
that the protein kinase YPK1, a yeast ortholog of the hu-
man kinase SGK1, was required for efficient FA uptake
from the environment. Since the yeast ortholog of the
human FA desaturase SCD1, OLE1, was only function-
ally active under conditions of sufficient oxygen supply,
yeast were not able to generate unsaturated lipids from de
novo synthesis in hypoxia. Thus, similar to the situation in
human cells mentioned above, hypoxic yeast became
dependent on increased FA uptake from their environ-
ment. Importantly, the deficiency in FA uptake in
YPK1-deficient hypoxic yeast cells could be rescued by
overexpression of human SGK1.
Here, we now provide evidence that human SGK1
plays a similar role in FA uptake and survival of hypoxic
human cancer cells suggesting a functional conservation
of YPK1/SGK1 in FA uptake in hypoxia. Our assumption
is based on the following findings: i) we observed a pro-
nounced up-regulation in the expression of SGK1 in
response to acute severe hypoxia in parental and anoxia-
tolerant NCI-H460 cancer cells; ii) Increased SGK1 ex-
pression in severe hypoxia correlated with a significant
increase in the uptake of fluorescent FA in both cell
lines; iii) Treatment with SGK1 inhibitor led to a signifi-
cant decrease in FA uptake and this was associated with
a pronounced eradication of hypoxic cancer cells.
The toxic effect of serum deprivation in severe hypoxia
could be rescued in both cell lines by the addition of the
unsaturated FA oleic acid; in contrast, the addition of
the saturated FA palmitic acid was highly toxic. This
finding supports the assumption that SCD1 is inhibited
under severe hypoxia and is reminiscent of observations
made in normoxic cancer cells exposed to pharmaco-
logical inhibition of SCD1 where the cells could only be
rescued by unsaturated FA with cis-configuration such
as oleic acid, whereas unsaturated FA in trans-configur-
ation such as elaidic acid provided only a limited protec-
tion [18]. The authors of this study attributed this
effect to the predominant cis-configuration of unsatur-
ated FA in cellular membranes [18]. Furthermore, ex-
cessive accumulation of long-chain FA, particularly
saturated FA such as palmitic acid, was shown to trigger
cell stress and cellular dysfunction in rat neonatal cardi-
omyocytes, adipocytes, mouse embryonic fibroblasts and
chinese hamster ovary cells even in normoxia [43–45].
In this context, excessive accumulation of saturated FA
Fig. 5 Model of SGK1´s role in FA uptake in hypoxia. In general, cells grown in normoxia generate (mono-)unsaturated FA from saturated stearic
and palmitic acid by oxygen-dependent desaturation performed by SCD1. In normoxia, FA synthesis emerges predominantly from glucose metabolites
and only to a little extent from glutamine. Blocking the process of oxygen-dependent desaturation by hypoxia-induced inhibition of SCD1 leads to
increased dependence of cancer cells on the uptake of (mono-)unsaturated FA from the environment. We provide evidence for a role of SGK1 in FA
uptake in NCI-H460 lung cancer cells exposed to severe hypoxia that may at least partially contribute to the radiosensitizing effect of SGK1-inhibition
in anoxia-tolerant NCI-H460 cancer cells with increased resistance to radiation-induced apoptosis
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was shown to trigger the unfolded protein response
(UPR), disruption of ER structure and cell death [44, 46].
Due to protective effect of desaturation in normoxia,
SCD1 prevents the accumulation of cell-damaging lipid
intermediates and thus an induction of apoptosis. How-
ever, this process is abrogated under hypoxia providing a
potential explanation for the high toxicity of palmitic acid
supplementation to serum-deprived NCI-H460 cells in se-
vere hypoxia. On the other hand, triglycerides are able to
bind palmitic acid to some extent, thereby preventing
their pro-apoptotic effects [45, 47]. However, triglycerides
generated in the presence of high amounts of palmitic
acid are of minor value in cellular processes and may thus
indirectly contribute to the so-called “lipid toxicity” of
saturated FA [45]. As an example, triglycerides pro-
duced from unsaturated FA provide important building
blocks for ceramide synthesis. The ability to incorporate
oleic acid instead of palmitic acid into triglycerides may
therefore explain why the addition of oleic acid together
with palmitic acid abrogated the toxic effects of palmitic
acid in severe hypoxia in our study. Altogether our obser-
vations underline the importance of supplementation and
uptake of unsaturated FA for cell survival in hypoxia.
Interestingly, inhibition of SGK1 in serum-deprived
NCI-H460 cells abrogated the observed rescue effect of
oleic acid supplementation in severe hypoxia pointing to
additional roles of SGK1 for cell survival apart from the
regulation of FA uptake. This assumption is further sup-
ported by the observation that SGK1 inhibition also
exerted toxic effects in normoxia. This is consistent with
the recent findings that siRNA-induced down-regulation
of SGK1 significantly reduced cell proliferation and sur-
vival in myeloma cells in normoxia [48].
We therefore speculate that SGK1 has additional roles
for the survival of cancer cells. This highly conserved
kinase is expressed in various tissue types in mammals
and plays an important role in the cellular stress re-
sponse. Of note SGK1 is involved in the regulation of
membrane localization and function of various ion chan-
nels and nutrient transporters [31, 49–51]. For example,
phosphorylation by SGK1 triggers activation and trans-
location of the glucose transporter GLUT1 to the plasma
membrane [29, 52, 53]. In addition, SGK1 regulates vari-
ous amino acid and peptide transporters responsible for
the transport of nutrients (amino acids and oligopep-
tides) across the cellular membrane that are essential for
cell proliferation and survival [31, 52–54]. Though SGK1
may not be required for maintenance of basic functions
of ion channels and nutrient transporters [29, 31, 55],
their SGK1-dependent regulation could become relevant
under pathological conditions such as tumor growth.
Here we add a novel aspect to the function of SGK1,
namely regulation of FA uptake that was essential to the
survival of cancer cells in severe hypoxia. We speculate
that the role played by SGK1 in the regulation of nutrient
uptake make the kinase an attractive therapeutic target for
cancer cells with high metabolic demand, particularly in
solid tumors with pronounced hypoxia.
In an effort to translate these novel findings in a more
clinically relevant setting we finally demonstrated that
inhibition of SGK1 is suited to increase the efficacy of
ionizing radiation in NCI-H460 cells. Our results cor-
roborate earlier in vitro findings on a significant increase
in apoptosis and cell death of Caco-2 colon carcinoma
cells by combined treatment with ionizing radiation and
SGK1 inhibition [56]. Furthermore, SGK1 inhibition
blocked tumor progression and had a radiosensitizing ef-
fect in a preclinical hepatocellular carcinoma (HCC)
model in vivo and in vitro [57]. However, we demonstrate
for the first time that SGK1-inhibition has also a potent
radiosensitizing effect in a lung adenocarcinoma cell
model in severe hypoxia, including anoxia-tolerant NCI-
H460 cancer cells, and that this effect may at least partially
be linked to reduced uptake of FA and other nutrients.
Interestingly, radiation itself was reported to trigger
the up-regulated expression of SGK1 which together
with other up-regulated proteins involved in prolifera-
tion and metabolic pathways promoted carcinogenesis in
mouse mammary gland [58]. Furthermore, a recent
study demonstrated that radiation changes the metabol-
ite pattern in the tumor extracellular fluid as well as in
the serum of irradiated cancer patients [59]. We specu-
late that SGK1 participates in stress-induced alterations
in the transport of nutrients and metabolites across cel-
lular membranes thereby promoting cell survival in cells
exposed to severe hypoxia, ionizing radiation, or both.
However, more detailed investigations are needed to un-
ravel the exact mechanisms by which SGK1 increases
cell survival and radioresistance to further explore SGK1
as therapeutic target in radiotherapy.
Conclusions
Taken together our results demonstrate a key role of
SGK1 in FA uptake and survival of NCI-H460 cancer
cells in severe hypoxia and its use as therapeutic target
for radio-sensitization. The finding that SGK1 inhibition
was particularly effective in sensitizing radioresistant
anoxia-tolerant NCI-H460 cancer cells to the cytotoxic
effects of ionizing radiation under conditions of severe
hypoxia provides new options for maximizing the effect
of radiotherapy by pharmacological inhibition of molecu-
lar targets, like SGK1 that become essential to cancer
cell survival in chronically hypoxic tumor fractions.
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